The role of galectins‑1, 3, 7, 8 and 9 as potential diagnostic and therapeutic markers in ovarian cancer (Review)
- Authors:
- Aleksandra Mielczarek‑Palacz
- Zdzisława Kondera‑Anasz
- Marta Smycz‑Kubańska
- Aleksandra Englisz
- Aleksandra Janusz
- Patrycja Królewska‑Daszczyńska
- Dominika Wendlocha
-
Affiliations: Department of Immunology and Serology, School of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40‑055 Katowice, Poland - Published online on: March 15, 2022 https://doi.org/10.3892/mmr.2022.12682
- Article Number: 166
-
Copyright: © Mielczarek‑Palacz et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Kossai M, Leary A, Scoazec JY and Genestie C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kroeger PT and Drapkin R: Pathogenesis and heterogeneity in ovarian cancer. Curr Opin Obstet Gynecol. 29:26–34. 2017. View Article : Google Scholar : PubMed/NCBI | |
Labrie M, De Araujo LOF, Communal L, Mes-Masson AM and St-Pierre Y: Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers. Sci Rep. 7:13242017. View Article : Google Scholar : PubMed/NCBI | |
Dubé-Delarosbil C and St-Pierre Y: The emerging role of galectins in high-fatality cancers. Cell Mol Life Sci. 75:1215–1226. 2018. View Article : Google Scholar : PubMed/NCBI | |
Compagno D, Gentilini LD, Jaworski FM, Pérez IG, Contrufo G and Laderach DJ: Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology. 24:899–906. 2014. View Article : Google Scholar : PubMed/NCBI | |
Thijssen VL, Rabinovich GA and Griffioen AW: Vascular galectins: Regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev. 24:547–558. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dings RP, Miller MC, Griffin RJ and Mayo KH: Galectins as molecular targets for therapeutic intervention. Int J Mol Sci. 19:905–927. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wdowiak K, Francuz T, Gallego-Colon E, Ruiz-Agamez N, Kubeczko M, Grochoła I and Wojnar J: Galectin targeted therapy in oncology: Current knowledge and perspectives. Int J Mol Sci. 19:210–231. 2018. View Article : Google Scholar : PubMed/NCBI | |
Balan V, Nangia-Makker P and Raz A: Galectins as cancer biomarkers. Cancers (Basel). 2:592–610. 2010. View Article : Google Scholar : PubMed/NCBI | |
Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT and Iacobelli S: Galectins and their ligands: Amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23:313–320. 2002. View Article : Google Scholar : PubMed/NCBI | |
Camby I, Le Mercier M, Lefranc F and Kiss R: Galectin-1: A small protein with major functions. Glycobiology. 16:137R–157R. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, et al: Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res. 7:311–318. 2009. View Article : Google Scholar : PubMed/NCBI | |
Anginot A, Espeli M, Chasson L, Mancini SJ and Schiff C: Galectin1 modulates plasma cell homeostasis and regulates the humoral immune response. J Immunol. 190:5526–5533. 2013. View Article : Google Scholar : PubMed/NCBI | |
Sandberg TP, Oosting J, van Pelt G, Mesker WE, Tollenaar RAEM and Morreau H: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio-increased expression of galectin-1 in tumors with high stromal content. Oncotarget. 9:31502–31515. 2018. View Article : Google Scholar : PubMed/NCBI | |
Satelli A, Rao PS, Gupta PK, Lockman PR, Srivenugopal KS and Rao US: Varied expression and localization of multiple galectins in different cancer cell lines. Oncol Rep. 19:587–594. 2008.PubMed/NCBI | |
Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1473:172–185. 1999. View Article : Google Scholar : PubMed/NCBI | |
Sundblad V, Morosi LG, Geffner JR and Rabinovich GA: Galectin-1: A Jack-of-All-Trades in the resolution of acute and chronic inflammation. J Immunol. 199:3721–3730. 2017. View Article : Google Scholar : PubMed/NCBI | |
Perillo NL, Pace KE, Seilhamer JJ and Baum LG: Apoptosis of T cells mediated by galectin-1. Nature. 378:736–739. 1995. View Article : Google Scholar : PubMed/NCBI | |
Rabinovich GA, Iglesias MM, Modesti NM, Castagna LF, Wolfenstein-Todel C, Riera CM and Sotomayor CE: Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: Biochemical and functional characterization. J Immunol. 160:4831–4840. 1998.PubMed/NCBI | |
Matarrese P, Tinari A, Mormone E, Bianco GA, Toscano MA, Ascione B, Rabinovich GA and Malorni W: Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem. 280:6969–6985. 2005. View Article : Google Scholar : PubMed/NCBI | |
Dias-Baruffi M, Zhu H, Cho M, Karmakar S, McEver RP and Cummings RD: Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis. J Biol Chem. 278:41282–41293. 2003. View Article : Google Scholar : PubMed/NCBI | |
Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP and Cummings RD: Human galectins-1, −2, and −4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood. 109:219–227. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hernandez JD and Baum LG: Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology. 12:127–136. 2002. View Article : Google Scholar : PubMed/NCBI | |
Sturm A, Lensch M and Andre S: Human galectin-2: Novel inducer of T cell apoptosis with distinct profile of caspase activation. J Immunol. 173:3825–3837. 2004. View Article : Google Scholar : PubMed/NCBI | |
Fuertes MB, Molinero LL, Toscano MA, Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW and Rabinovich GA: Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem. 267:177–185. 2004. View Article : Google Scholar : PubMed/NCBI | |
Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL and Rabinovich GA: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: A potential mechanism of tumor-immune privilege. Cancer Cell. 5:241–251. 2004. View Article : Google Scholar : PubMed/NCBI | |
Toscano MA, Commodaro AG, Ilarregui JM, Bianco GA, Liberman A, Serra HM, Hirabayashi J, Rizzo LV and Rabinovich GA: Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol. 176:6323–6332. 2006. View Article : Google Scholar : PubMed/NCBI | |
Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG and Rabinovich GA: Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol. 8:825–834. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kuo PL, Huang MS, Cheng DE, Hung JY, Yang CJ and Chou SH: Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764. 2012. View Article : Google Scholar : PubMed/NCBI | |
Soldati R, Berger E, Zenclussen AC, Jorch G, Lode HN, Salatino M, Rabinovich GA and Fest S: Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer. 131:1131–1141. 2012. View Article : Google Scholar : PubMed/NCBI | |
Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR and Rabinovich GA: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol. 10:981–991. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol. 188:3127–3137. 2012. View Article : Google Scholar : PubMed/NCBI | |
Baatar D, Olkhanud PB, Wells V, Indig FE, Mallucci L and Biragyn A: Tregs utilize beta-galactoside-binding protein to transiently inhibit PI3K/p21ras activity of human CD8+ T cells to block their TCR-mediated ERK activity and proliferation. Brain Behav Immun. 23:1028–1037. 2009. View Article : Google Scholar : PubMed/NCBI | |
Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R and Lechler RI: Galectin-1: A key effector of regulation mediated by CD4+CD25+ T cells. Blood. 109:2058–2065. 2007. View Article : Google Scholar : PubMed/NCBI | |
Espeli M, Mancini SJ, Breton C, Poirier F and Schiff C: Impaired B-cell development at the pre-BII-cell stage in galectin-1-deficient mice due to inefficient pre-BII/stromal cell interactions. Blood. 113:5878–5886. 2009. View Article : Google Scholar : PubMed/NCBI | |
Mourcin F, Breton C, Tellier J, Narang P, Chasson L, Jorquera A, Coles M, Schiff C and Mancini SJ: Galectin-1-expressing stromal cells constitute a specific niche for pre-BII cell development in mouse bone marrow. Blood. 117:6552–6561. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tsai CM, Chiu YK, Hsu TL, Lin IY, Hsieh SL and Lin KI: Galectin-1 promotes immunoglobulin production during plasma cell differentiation. J Immunol. 181:4570–4579. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Yao Y, Sun L and Tang J: Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer. J Cancer. 8:3733–3741. 2017. View Article : Google Scholar : PubMed/NCBI | |
Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI | |
Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, Song SY, Lee YY, Choi CH, Kim TJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI | |
Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S and Jeschke U: Galectins-1, −3, and −7 are prognostic markers for survival of ovarian cancer patients. Int J Mol Sci. 18:12302017. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Yao Y, Sun L, Zhou J, Liu J, Wang J, Li J and Tang J: Clinical implication of the serum galectin-1 expression in epithelial ovarian cancer patients. J Ovarian Res. 8:782015. View Article : Google Scholar : PubMed/NCBI | |
Abdelwahab M, Ebian H, Ibrahim T, Badr M, Lashin M, Yassin M, Ismail A and Obaya A: Clinical significance of serum galectin-1 and its tissue immunohistochemical expression in serous ovarian carcinoma patients. J Obstet Gynecol. 9:937–953. 2019. | |
Argüeso P and Panjwani N: Focus on molecules: Galectin-3. Exp Eye Res. 9:2–3. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pinnelli V, Sirsiker M and Silvia WD: Galectin-3: A novel biomarker. Int J Chem Pharm Res. 2:81–94. 2013. | |
Lityńska A and Pokrywka M: Structure and biological functions of galectin-3 Część Part I. Post Biol Kom. 37:677–684. 2010. | |
Pokrywka M and Lityńska A: Structure and biological functions of galectin-3 Part II. Post Biol Kom. 37:685–697. 2010. | |
Ruvolo P: Galectin-3 as a guardian of the tumor microenvironment. Biochim Biophys Acta. 1863:427–437. 2016. View Article : Google Scholar : PubMed/NCBI | |
Gudowska M and Chrostek L: Diagnostic role of galectin-3. Pol Merkur Lekarski. 222:408–412. 2014.(In Polish). PubMed/NCBI | |
Li M, Feng YM and Fang SQ: Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 50:5356–5365. 2017. View Article : Google Scholar | |
Wdowiak K, Spychałowicz W, Fajkis M and Wojnar J: Galectins in hematological malignancies-role, functions and potential therapeutic targets. Postepy Hig Med Dosw (Online. 70:95–103. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI | |
Punt S, Thijssen VL, Vrolijk J, de Kroon CD, Gorter A and Jordanova E: Galectin-1, −3 and −9 expression and clinical significance in squamous cervical cancer. PLoS One. 10:e01291192015. View Article : Google Scholar : PubMed/NCBI | |
Vladoiu MC, Labrie M and St-Pierre Y: Intracellular galectins in cancer cells: Potential new targets for therapy (Review). Int J Oncol. 44:1001–10014. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chetry M, Thapa S, Hu X, Song Y, Zhang J, Zhu H and Zhu X: The role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J Cancer. 9:4742–4755. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wang L, Zhao Y, Wang Y and Wu X: The role of galectins in cervical cancer biology and progression. Biomed Res Int. 2018:21759272018.PubMed/NCBI | |
Farhad M, Rolig A and Redmond W: The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 7:e14344672018. View Article : Google Scholar : PubMed/NCBI | |
Lee JH, Zhang X, Shin BK, Lee ES and Kim I: Mac-2 binding protein and galectin-3 expression in mucinous tumors of the ovary: An annealing control primer system and immunohistochemical study. Pathology. 41:229–233. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI | |
Brustmann H: Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol. 27:380–389. 2008. View Article : Google Scholar : PubMed/NCBI | |
Lu H, Liu Y, Wang D, Wang L, Zhou H, Xu G, Xie L, Wu M, Lin Z and Yu Y: Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway. Tumour Biol. 37:11469–11477. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W and Chun KH: Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 7:68229–68241. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL and Nguyen DD: Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 135:573–579. 2014. View Article : Google Scholar : PubMed/NCBI | |
Eliaz I: The role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol. 6:343–349. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hossein G, Keshavarz M, Ahmadi S and Naderi N: Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 14:7561–7568. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hossein G, Halvaei S, Heidarian Y, Dehghani-Ghobadi Z, Hassani M, Hosseini H, Naderi N and Sheikh Hassani S: Pectasol-C modified citrus pectin targets galectin-3-induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids. Cancer Med. 8:4315–4329. 2019. View Article : Google Scholar : PubMed/NCBI | |
Cai G, Ma X, Chen B, Huang Y, Liu S, Yang H and Zo W: Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signalingactivation. Tumour Biol. 37:11883–11891. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wang D, You D and Li L: Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function. J Toxicol Sci. 44:47–56. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bieg D, Sypniewski D, Nowak E and Bednarek I: Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 298:1181–1194. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bieg D, Sypniewski D, Nowak E and Bednarek I: MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kaur M, Kaur T, Kamboj S and Singh J: Roles of galectin-7 in cancer. Asian Pac J Cancer Prev. 17:455–461. 2016. View Article : Google Scholar : PubMed/NCBI | |
Menkhorst E, Griffiths M, van Sinderen M, Rainczuk K, Niven K and Dimitriadis E: Galectin-7 is elevated in endometrioid (type I) endometrial cancer and promotes cell migration. Oncol Lett. 16:4721–4728. 2018.PubMed/NCBI | |
Chou F, Chen H, Kuo C and Sytwu H: Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci. 19:430–441. 2018. View Article : Google Scholar : PubMed/NCBI | |
Johannes L, Jacob R and Leffler H: Galectins at a glance. J Cell Sci. 131:jcs2088842018. View Article : Google Scholar : PubMed/NCBI | |
Labrie M, Vladoiu MC, Grosset A, Gaboury L and St-Pierre Y: Expression and functions of galectin-7 in ovarian cancer. Oncotarget. 5:7705–7721. 2014. View Article : Google Scholar : PubMed/NCBI | |
Higareda-Almaraz JC, Ruiz-Moreno JS, Klimentova J, Barbieri D, Salvador-Gallego R, Ly R, Valtierra-Gutierrez IA, Dinsart C, Rabinovich GA, Stulik J, et al: Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment. BMC Cancer. 16:680–692. 2016. View Article : Google Scholar : PubMed/NCBI | |
St-Pierre Y: Towards a better understanding of the relationships between Galectin-7, p53 and MMP-9 during cancer progression. Biomolecules. 11:8792021. View Article : Google Scholar : PubMed/NCBI | |
Guo JP and Li XG: Galectin-7 promotes the invasiveness of human oral squamous cell carcinoma cells via activation of ERK and JNK signaling. Oncol Lett. 13:1919–1924. 2017. View Article : Google Scholar : PubMed/NCBI | |
Krześlak A: Akt kinase: A key regulator of metabolism and progression of tumors. Postepy Hig Med Dosw (Online). 64:490–503. 2010.(In Polish). PubMed/NCBI | |
Kim HJ, Jeon HK, Lee JK, Sung CO, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS and Lee JW: Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res. 33:1555–1561. 2013.PubMed/NCBI | |
Bibens-Laulan N and St-Pierre Y: Intracellular galectin-7 expression in cancer cells results from an autocrine transcriptional mechanism and endocytosis of extracellular galectin-7. PLoS One. 12:e01871942017. View Article : Google Scholar : PubMed/NCBI | |
Elola MT, Ferragut F, Cárdenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Troncoso MF, Compagno D, Wolfenstein-Todel C and Rabinovich GA: Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol Histopathol. 29:1093–1105. 2014.PubMed/NCBI | |
Zick Y, Eisenstein M, Goren RA, Hadari YR, Levy Y and Ronen D: Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconj J. 19:517–526. 2002. View Article : Google Scholar : PubMed/NCBI | |
Troncoso MF, Ferragut F, Bacigalupo ML, Cárdenas Delgado VM, Nugnes LG, Gentilini L, Laderach D, Wolfenstein-Todel C, Compagno D, Rabinovich GA and Elola MT: Galectin-8: A matricellular lectin with key roles in angiogenesis. Glycobiology. 10:907–914. 2014. View Article : Google Scholar : PubMed/NCBI | |
Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR and Rabinovich GA: Galectins: Matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI | |
Levy Y, Arbel-Goren R, Hadari YR, Eshhar S, Ronen D, Elhanany E, Geiger B and Zick Y: Galectin-8 functions as a matricellular modulator of cell adhesion. J Biol Chem. 276:31285–31295. 2001. View Article : Google Scholar : PubMed/NCBI | |
Troncoso MF, Elola MT, Croci DO and Rabinovich GA: Integrating structure and function of ‘tandem-repeat’ galectins. Front Biosci (Schol Ed). 4:864–887. 2012.PubMed/NCBI | |
Tribulatti MV, Carabelli J, Prato CA and Campetella O: Galectin-8 in the onset of the immune response and inflammation. Glycobiology. 30:134–142. 2020. View Article : Google Scholar : PubMed/NCBI | |
Ferragut F, Cagnoni AJ, Colombo LL, Sánchez Terrero C, Wolfenstein-Todel C, Troncoso MF, Vanzulli SI, Rabinovich GA, Mariño KV and Elola MT: Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta Mol Cell Res. 1866:1338–1352. 2019. View Article : Google Scholar : PubMed/NCBI | |
Fan J, Tang X, Wang Q, Zhang Z, Wu S, Li W, Liu S, Yao G, Chen H and Sun L: Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9. Stem Cell Res Ther. 9:237–349. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zhou X, Sun L, Jing D, Xu G, Zhang J, Lin L, Zhao J, Yao Z and Lin H: Galectin-9 expression predicts favorable clinical outcome in solid tumors: A systematic review and meta-analysis. Front Physiol. 9:4522018. View Article : Google Scholar : PubMed/NCBI | |
Fujihara S, Mori H, Kobara H, Rafiq K, Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy. Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lahm H, André S, Hoeflich A, Fischer JR, Sordat B, Kaltner H, Wolf E and Gabius HJ: Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol. 127:375–386. 2001. View Article : Google Scholar : PubMed/NCBI |